gene therapy- past, present and futuregene therapy- past, present and future mark a. kay md, phd...
TRANSCRIPT
Gene Therapy- Past, Present and Future
Mark A. Kay MD, PhDDennis Farrey Family Professor
Departments of Pediatrics and GeneticsStanford University
Definition of gene therapy
Gene therapy is the introduction of nucleic acids (e.g. DNA/genes) into somatic cells of the body to correct or prevent a pathological process
Think of DNA as a class of pharmaceuticals
•Fix a gene change the DNA-mutation repair
•Silence a gene-from a pathogen,gain of function mutation
What Do We Want to Accomplish?
•Add a gene-restore a missing gene function or supply an RNA or protein that has pharmacological effect
Vector Categories
Viral-Based-Manipulating Natural
Existing Viruses to Transfer
Therapeutic Genes
Non-Viral- DNA Molecules Delivered
as Naked DNA, Lipids, or Polymers
Which vectors are in use?
What diseases are being targeted?
Potential factors limiting vector efficacy
Adeno-associated viruses
Discovered in mid 1960s as a contaminant
Family: ParvoviridaeSubfamily: ParvovirinaeGenus: Dependoparvovirus
AAV Vectors
CapRep DNA
AAV
ITR
Therapeutic geneControlelement
Gene Cassette
DNA
AAV Vectors
ITR ITR
ITR
AAV vector production strategies: Helper virus-free system
Therapeutic gene
ITRITR
pVector
CapRep
pHLP
pladenoE2A
E4VA
CaPO4
Transfection in 293 cells
Vector recovery
Alternative Production Methods
Purification Schemes
• Various Physical Separation methods
• Vector purity (e.g. advential agents, DNA contamination)
• Full to Empty Capsid Ratio
• Capsid Composition
rAAV-mediated transgene expression in vivo
AAV-EF1a-hFIX to C57BL/6 mice
1000
100
10
0 2 4 6 8 10
hF
IX (
ng
/ml)
Months
Snyder et al., Nat. Genetics 1997
Nature Genetics, 1997
First Hemophilia A dog
Dogs are treatedDog colonies are University of North Carolina at Chapel Hill
Dogs treated with AAV-FIX vectors
Expression for > 7 years
Hemophilia B dog
Kenneth M. Brinkhous at the University of North Carolina at Chapel Hill
Biotech - Academic Collaboration
• The ultimate goals are the same• The acute similarities & differences
• Disclosures• IP restrictions• Survival –publish vs perish
shareholders
First systemic administration of an AAV vector into a human
Manno et al., Nature Medicine 2006
Successful transduction of liver in hemophilia by AAV-Factor IX and
limitations imposed by the immune host response hemophilia
• Therapeutic hFIX was demonstrated in a human
• Unlike all animal models expression in humans was temporary
• This limitation was likely related to a cell mediated immune directed against hepatocytes containing capsid particles
• No matter how good the animal models one cannot predict the outcome in humans until you try it in people
Manno et al., Nature Medicine 2006
Surprises along the way
• Jessie Gelsinger’s Death
• Seminal Fluid PCR detection of vector DNA genomes--- how to establish significance
• Unexplained Transaminitis
Pseudotyping recombinant vector genomes
• AAV-2 is prototype vector-isolated from humans
• Most of the population exposed (e.g. immunity)
• Cell-mediated immune responses
• Small number of amino acid changes can have profound effects
• on the transduction parameters (immunity, efficiency, cell type)
AAV2AAV1 AAV3
AAV4 AAV5 AAV6
Nathwani et al., New England Journal of Medicine 2011
AAV-2/8 Gene Therapy for Hemophilia B
AAV-8 is not an optimal vector
for human gene transfer
• Some humans pre-existing immunityinhibiting any gene transfer
• Dose response in human is >10x less than expected based on animal studies
Various AAV-clinical trials for
Hemophilia B ongoing
• Additional patients with better dosing
• What about patients with pre-existing immunity?
• What happens if expression wanes over time?
• How long will it last if treated at birth?
How does one predict clinical outcomes from animal studies?
Which animals models are most predictive?
Reconstitution of mouse liver with human hepatocytes
AV shuffle library screening in FRG mice
Succinylacetone
Hpd-/-NTBC
HT1 Fah-/-
Tyrosine
P-hydroxy-phenylpyruvate
AcetoacetateFumarate
Fumarylacetoacetate (FAA)
Maleylacetoacetate (FAA)
Homogentistisic acid (HGA)
Azuma et al., Nature Biotechnology 2007
Molecular
shuffling and
evolution of new
viruses
Kay, M.A. Nature Reviews Genetics 2011
AAV shuffle library selection in Tissue Culture Cells
TC cells
Harvest supernatanton day 3 post infection
AAV library (MOI range)hAd5 (fixed predetermined MOI)
Western Blot analysis
Select dilution with the lowestexpression of AAV proteins
VP1VP2VP3
Library MOI
•Vector DNA extraction
•PCR amplification of CAP gene
• TOPO subcloning
• Sequencing
Human IVIG negative selection
Library screening in mice with humanized liver
Lisowski et al., Nature 2014
Vectorization of AAV capsids obtained from in vivo screen
Lisowski et al., Nature 2014
Limitations to conventional rAAVapproaches
• Loss of transgene expression in growing or dividing cells
• Risk of insertional mutagenesis
• Problems with re-administration
• Genome size
• Pre-existing immunity
• Cell-mediated immunity
Genome editing
without nucleases
ITRhF92A
5’ homology arm to Alb 3’ homology arm to Alb
… …Wild-type Alblocus
Targeted Alblocus ……
RNA: Fused mRNA
Protein: +
Stop
P hF9
Alb
Alb 2A
DNA:
AAV8 capsid
hF92A
hF92A
Promoterless Gene Targeting Without Nucleases
Barzel et al., Nature 2014
Promoterless Gene Targeting for hFIX
Improved Human Capsid + Gene Ride
• Treat non-quiescent tissues including neonatal
liver. No retreatment with rAAV required
• Abrogates hepatic genotoxicity (hepatocellular carcinoma)
• No genotoxicity or immunogenicity associated with nucleases
• Endogenous gene regulation
Where do we go from here?